AS 1403

Drug Profile

AS 1403

Alternative Names: TheraFab

Latest Information Update: 08 Sep 2003

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Antisoma
  • Class Antineoplastics; Fab fragments; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Lung cancer; Non-small cell lung cancer

Most Recent Events

  • 08 Sep 2003 Discontinued - Phase-I for Lung cancer in United Kingdom (IV)
  • 08 Sep 2003 Discontinued - Phase-I for Non-small cell lung cancer in Australia (IV)
  • 08 Sep 2003 Discontinued - Phase-I for Non-small cell lung cancer in Europe (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top